Positive Analyst Ratings and Price Targets for 4D Molecular Therapeutics
As of February 7, 2024, 4D Molecular Therapeutics (NASDAQ:FDMT) has garnered favorable analyst ratings. The consensus among 5 Wall Street ...
© 2024 Stocks Today
Tag: FDMT
Encouraging Phase 2 Results and Raised Target Price for 4D Molecular Therapeutics Wet AMD Treatment
On February 6, 2024, 4D Molecular Therapeutics (4DMT) unveiled promising preliminary findings from the Phase 2 PRISM clinical trial, which ...
4D Molecular Therapeutics Receives Rare Pediatric Disease Designation for Groundbreaking Cystic Fibrosis Treatment
On January 23, 2024, 4D Molecular Therapeutics (4DMT) celebrated a significant milestone as they were granted the esteemed Rare Pediatric ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Unlocking the Future: The Rise of Open-Source FPGA Development Tools